Wednesday, 20 November 2019

Alnylam's rare genetic disorder drug gets early U.S. approval

Alnylam Pharmaceuticals Inc on Wednesday received an early U.S. approval for its gene silencing drug to treat patients with a rare genetic disorder that can cause severe pain.


Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)